Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)

A Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)

Phase II clinical trial to evaluate the efficacy and safety of YKYY032 injection in adults with hyperlipoproteinemia (a)

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a randomized, double-blind, parallel, placebo-controlled Phase II clinical study, aiming to evaluate the efficacy and safety of YKYY032 injection in adult patients with hyperlipoproteinemia (a).

Tipo di studio

Interventistico

Iscrizione (Stimato)

192

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100034
        • Peking University First Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Before starting any research on a specific activity/program, a written informed consent must be provided;

  2. For both males and females, the age at signing the Informed Consent Form (ICF) should be between 18 and 80 years;

  3. The body mass index should be within the range of 18.5 - 40 kg/㎡ (including the boundary values);

  4. During the pre-screening period (if any) and the screening period, the fasting Lp(a) measured in the central laboratory of the trial participants should be ≥ 150 nmol/L;

  5. According to one of the following criteria, the participants are clinically diagnosed with ASCVD, including but not limited to:

    1. Having a history of coronary artery revascularization through percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG);
    2. Diagnosed with coronary artery disease, with or without a previous myocardial infarction;
    3. Diagnosed with atherosclerotic cerebrovascular disease;
    4. Diagnosed with peripheral artery disease; or without a clinical history of ASCVD, but meeting the definition of high-risk individuals for ASCVD in the overall risk assessment flowchart for ASCVD in Chinese lipid management guidelines (2023) (see Appendix 16.1 for the overall risk assessment flowchart for ASCVD in Chinese adults);
  6. For the trial participants who receive the following drug treatments, their treatment plans must be stable for at least 4 weeks before signing the screening ICF, and are expected to remain stable until the end of the follow-up period after the last administration of the trial drug:

    1. Lipid-lowering drugs (statins, ezetimibe, PCSK9 inhibitors, niacin, fibrates, fish oil or other products containing ω-3 fatty acids, including over-the-counter drugs [OTC]);
    2. Testosterone, estrogen, anti-estrogen, progesterone, progestin, selective estrogen receptor modulators and growth hormone.
  7. Female trial participants are not pregnant or breastfeeding; fertile female and male trial participants must have an acceptable contraceptive method from the time of signing the ICF until 12 months after the last administration of the trial drug (see Appendix 16.2 for the requirements for trial participants' contraception); males are not allowed to donate sperm, and females are not allowed to donate eggs;

  8. They are willing to follow the research procedures stipulated in this protocol (including follow-up) and are willing to cooperate fully with the researchers.

Exclusion Criteria:

  1. Clinical evidence of active liver disease or liver dysfunction in the past or currently exists, defined as AST or ALT ≥ 2 times the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5 times the ULN at the screening period (except for participants diagnosed with Gilbert syndrome);
  2. Estimated glomerular filtration rate (eGFR) calculated using the Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI) creatinine clearance formula is < 60 mL/min/1.73 ㎡ during the screening period;
  3. Any recent major cardiovascular event (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, unstable angina pectoris, coronary or peripheral artery revascularization, major cardiac surgery, stroke or transient ischemic attack, acute limb ischemia) or non-cardiac major surgery within 6 months before randomization;
  4. Any planned cardiac surgery, PCI or carotid artery stenting procedure during the study period, or planned non-cardiac major surgery;
  5. Moderate to severe heart failure (NYHA functional class III or IV at the screening period) or previously known left ventricular ejection fraction < 50%;
  6. Uncontrolled hypertension (systolic blood pressure [SBP] ≥ 160 mmHg or diastolic blood pressure [DBP] ≥ 100 mmHg);
  7. Presence of uncontrolled arrhythmia within 3 months before randomization, defined as recurrent and symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or drug-uncontrolled supraventricular tachycardia;
  8. Any malignancy within 5 years before randomization (successfully treated non-melanoma skin cancer, cervical carcinoma in situ, breast duct carcinoma, or stage 1 prostate cancer excluded);
  9. Any hereditary or other bleeding disorders;
  10. Fasting triglycerides ≥ 500 mg/dL (5.65 mmol/L) at the screening period;
  11. Fasting LDL-C ≥ 4.9 mmol/L (190 mg/dL) at the screening period;
  12. Presence of type 1 diabetes or poorly controlled type 2 diabetes (defined as requiring hospitalization for ketoacidosis or hyperosmolar hyperglycemic state, or glycated hemoglobin [HbA1c] ≥ 8.5% at the screening period, or hospitalization due to poor glycemic control) within 3 months before randomization;
  13. Uncontrolled hyperthyroidism or hypothyroidism (stable treatment with abnormal thyroid hormone or unrelieved clinical symptoms);
  14. Any active infection or major hematological, renal, metabolic, gastrointestinal or endocrine dysfunction requiring systemic antiviral or antimicrobial treatment by the investigator's judgment before randomization;
  15. Evidence of acute or chronic hepatitis B or hepatitis C at the screening period (positive for hepatitis B surface antigen [HBsAg]; or positive for hepatitis C antibody [HCV-Ab]), or human immunodeficiency virus (HIV) infection (positive for HIV antibody), or active syphilis infection (positive for Treponema pallidum antibody);
  16. Any ASO, small interfering RNA (siRNA) treatment (such as Inclisiran sodium injection) or any experimental treatment targeting Lp(a) within 12 months before randomization;
  17. Stable use of immunosuppressants, or stable use of corticosteroids (excluding topical/inhaled use) within 3 months before randomization (continuous use >14 days is considered stable use); or regular systemic corticosteroid use within 4 weeks before the first dose; or expected need for prednisone >20 mg/day or equivalent;
  18. Currently receiving, or having received lipoprotein apheresis within 3 months before randomization, or planning to receive lipoprotein apheresis during the study;
  19. Have homozygous familial hypercholesterolemia (HoFH) or have received lomitapide within 12 months prior to randomization;
  20. Are known to be allergic to any component of YKYY032 injection, or have a history or current severe allergic reaction;
  21. Have participated in or plan to participate in a drug clinical trial within 3 months prior to screening, or within the trial period (excluding non-interventional studies and those who only signed the ICF but did not receive study intervention);
  22. Have had or currently have drug abuse or alcoholism (for men, an average weekly alcohol intake of more than 14 units, for women, more than 7 units [1 unit = 360 mL beer; or 150 mL wine; or 45 mL distilled spirits]);
  23. Have received any known herbal medicine (including but not limited to: hawthorn, salvia miltiorrhiza), vitamin (including but not limited to: niacin), or supplement (including but not limited to: red yeast rice, omega-3 fatty acids) within 30 days prior to randomization, except for those who have been using lipid-lowering drugs stably for 4 weeks prior to screening (see item 6 of the inclusion criteria);
  24. Have had or currently have any underlying disease or mental condition that the investigator considers may affect the safety of the study participants during the study, or interfere with the participation or completion of the study, or affect the interpretation of data.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: YKYY032 group

Drug: YKYY032 Injection Subcutaneous administration of YKYY032 on Day 1 and Day 180 (2 doses, approximately 6 months apart)

Drug: YKYY032 Injection Subcutaneous administration of YKYY032 on Day 1 and Day 180 (2 doses, approximately 6 months apart)

Comparatore placebo: YKYY032 Placebo group

Drug: YKYY032 Placebo Subcutaneous administration of matching placebo on Day 1 and Day 180 (2 doses, approximately 6 months apart)

Drug: YKYY032 Placebo Subcutaneous administration of matching placebo on Day 1 and Day 180 (2 doses, approximately 6 months apart)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
The percentage change from baseline in time average Lp(a) over Days 60-180.
Lasso di tempo: Baseline, Days 60 - 180
Baseline, Days 60 - 180

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
The proportion of participants achieving Lp(a) < 125 nmol/L and < 75 nmol/L at Days 60, 180, 240, 360 and 540.
Lasso di tempo: Days 60, 180, 240, 360 and 540
Days 60, 180, 240, 360 and 540
The percentage change of Lp(a) from the baseline at Days 60, 180, 240, 360 and 540.
Lasso di tempo: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
The absolute value of the change of Lp(a) from the baseline at Days 60, 180, 240, 360 and 540.
Lasso di tempo: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
The percentage change of LDL-C from the baseline at Days 60, 180, 240, 360 and 540.
Lasso di tempo: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
The percentage change of ApoB from the baseline at Days 60, 180, 240, 360 and 540.
Lasso di tempo: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
The percentage change from baseline in other lipid parameters, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C) at Days 60, 180, 240, 360 and 540.
Lasso di tempo: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
Percent change in High-sensitivity C-reactive Protein (hsCRP) from baseline.
Lasso di tempo: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of YKYY032
Lasso di tempo: Day 1: pre-dose, post-dose 1-3 hours, 3-6 hours, 7-9 hours, 22-26 hours (Day 2), 46-50 hours (Day 3); Day 180: 1-3 hours, 3-6 hours, 7-9 hours, 22-26 hours (Day 181), 46-50 hours (Day 182) post-dose
Day 1: pre-dose, post-dose 1-3 hours, 3-6 hours, 7-9 hours, 22-26 hours (Day 2), 46-50 hours (Day 3); Day 180: 1-3 hours, 3-6 hours, 7-9 hours, 22-26 hours (Day 181), 46-50 hours (Day 182) post-dose
The incidence and severity of adverse events (TEAE); Vital signs, physical examination results, laboratory test results, 12-lead electrocardiogram (ECG), etc.
Lasso di tempo: During the clinical trial period, up to Day 540.
During the clinical trial period, up to Day 540.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

20 novembre 2026

Completamento primario (Stimato)

30 dicembre 2028

Completamento dello studio (Stimato)

31 maggio 2029

Date di iscrizione allo studio

Primo inviato

19 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

27 ottobre 2026

Primo Inserito (Effettivo)

3 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

27 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CLSP-YKYY032-Z02

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .